FUSEN PHARM's application for the consistency evaluation of Nicardipine Hydrochloride Injection has been approved for marketing

AASTOCKS
2025.12.14 09:49

FUSEN PHARM (01652.HK) announced that the consistency evaluation application for "Nicardipine Hydrochloride Injection" developed by its wholly-owned subsidiary Henan Fusen has been approved by the National Medical Products Administration of China, approved for emergency management of abnormal hypertension during surgery and hypertensive emergencies

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.